Lancashire and South Cumbria
Formulary
Formulary
9 Nutrition and blood
09-08-01 Drugs used in metabolic disorders
| Asfotase alfa Strensiq® |
|
Formulary
|
Solution for injection Tertiary Centre Only. |
 NICE: Asfotase alfa for treating paediatric-onset hypophosphatasia |
|
| Avalglucosidase alfa Nexviadyme® |
|
Formulary
|
Powder for concentrate for solution for infusion 100mg Under expert supervision. |
|
NICE TA821: Avalglucosidase alfa for treating Pompe disease |
|
|
| Eladocagene exuparvovec Upstaza® |
|
Formulary
|
Solution for infusion 2.8 × 1011 vector genomes (vg)/0.5 mL Tertiary Centre Only. |
|
|
| Eplontersen Wainzua® |
|
Formulary
|
Solution for injection 45 mg/0.8 ml |
|
NICE TA1020: Eplontersen for treating hereditary transthyretin-related amyloidosis |
|
|
| Lumasiran Oxlumo ® |
|
Formulary
|
Solution for injection 94.5mg/0.5mL Tertiary Centre Only. |
|
NICE HST25: Lumasiran for treating primary hyperoxaluria type 1 |
|
|
| Pegunigalsidase alfa Elafbrio® |
|
Formulary
|
Concentrate for solution for infusion 20mg/10ml, 5mg/2.5ml Under expert supervision. |
|
NICE TA915: Pegunigalsidase alfa for treating Fabry disease |
|
|
| Vutrisiran Amvuttra® |
|
Formulary
|
Solution for injection pre-filled syringe 25mg/0.5ml Under expert supervision. Females of childbearing potential should use effective contraception during treatment; if conception is planned, vutrisiran and vitamin A supplementation should be stopped and vitamin A levels monitored - consult product literature. |
|
NICE TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis |
|
|
Links
Biosimilars policy statement- LSCMMG shared care guideline - penicillamine
- LSCMMG: Bariatric surgery guidelines for prescribing of vitamins and nutritional supplements: Position Statement
- LSCMMG: Gluten-Free food products: Position Statement
- LSCMMG: Oral Nutritional Supplements in Primary Care
- LSCMMG: Penicillamine shared care guideline
- LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children
- Medicines for children: Carnitine for metabolic disorders
- NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
- NICE HST23 Asfotase alfa for treating paediatric-onset hypophosphatasia
- NICE HST25: Lumasiran for treating primary hyperoxaluria type 1
- NICE HST26 Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency
- NICE NG20: Coeliac disease: recognition, assessment and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE TA 915:Pegunigalsidase alfa for treating Fabry diease
- NICE TA1020: Eplontersen for treating hereditary transthyretin-related amyloidosis
- NICE TA821: Avalglucosidase alfa for treating Pompe disease
- NICE TA821: Avalglucosidase alfa for treating Pompe disease
- NICE TA868 Vutrisiran for treating hereditary transthyretin-related amyloidosis
- NICE TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis
- NICE TA915: Pegunigalsidase alfa for treating Fabry disease
- NICE: Asfotase alfa for treating paediatric-onset hypophosphatasia